NRX Pharmaceuticals Wins $11.2 Million DARPA Contract to Run 18-Month SPARC-TMS Trial
NRX Pharmaceuticals, via subsidiary NRx Defense Systems, secured an $11.2M contract with DARPA for an 18-month SPARC-TMS trial in treatment-resistant depression. The deal includes $6.7M initially obligated, with payments tied to milestones. The FDA-approved trial is set to begin patient enrollment. According to the SEC filing, the contract advances the SPARC-TMS trial.
How this was made
The 30-second read
Why it matters
The DARPA contract adds $11.2M in non‑dilutive capital, extending the company's cash runway and potentially de‑risking its SPARC‑TMS program.
Market read
The award is a material catalyst for NRX, likely prompting short‑term buying interest.
What to watch
DARPA retains license rights; future commercialization may require additional partnerships.
Background
NRX Pharmaceuticals is a clinical‑stage biotech focused on neuromodulation therapies.
Ticker impact
NRX Pharmaceuticals secured an $11.2M DARPA contract for an 18‑month SPARC‑TMS trial in treatment‑resistant depression.
likely upward pressure as investors price in the new funding and trial progress.
DARPA award adds $11.2M cash and milestone payments, improving cash runway and validating the technology.
Market effects
May boost sentiment in the biotech/psychiatric‑treatment sector as a government contract validates the approach.
Limited to U.S. biotech investors; no broader regional effect.
Minor global impact; primarily relevant to niche biotech investors.
Counterpoint
The trial could face regulatory or efficacy setbacks, making the funding less meaningful.
Key entities
- companyNRX Pharmaceuticals
Biotech developer of SPARC‑TMS therapy.
- government_agencyDARPA
U.S. Defense Advanced Research Projects Agency, contract issuer.
